Press Releases

ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profile Meiji Seika Pharma submitted ARCT-154 New Drug Application in Japan New ARCT-154 booster clinical data demonstrate one-year durability across a panel of variants

Arcturus to present at the Canaccord Genuity 43 rd Annual Growth Conference , August 9, 2023 SAN DIEGO --(BUSINESS WIRE)--Jul. 24, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the

SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare

New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan , leading to potential approval in 2023 $23.6 Million advanced for the manufacturing and supply of ARCT-154 ARCT-032 Phase 1 enrollment and administration completed successfully; trial expansion to

SAN DIEGO --(BUSINESS WIRE)--Apr. 26, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

$200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-810 Phase 2 multiple ascending

Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day, April 3, 2023 SAN DIEGO --(BUSINESS WIRE)--Mar. 7, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused

SAN DIEGO --(BUSINESS WIRE)--Feb. 6, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

SAN DIEGO --(BUSINESS WIRE)--Jan. 31, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities

SAN DIEGO --(BUSINESS WIRE)--Dec. 19, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and